01—Abstract
Summary
Summary of the 8-K filed January 16, 2026. Cited figures are marked; the original filing is the authoritative source.
Kenvue Inc. (KVUE) filed this Form 8-K on January 16, 2026 to voluntarily supplement the Joint Proxy Statement/Prospectus for its proposed merger with Kimberly-Clark Corporation (K-C), under the Merger Agreement dated November 2, 2025.
Under the agreement, Kenvue becomes a direct wholly owned subsidiary of K-C in a two-step merger, and Kenvue stockholders are to receive $3.50a per share in cash plus K-C shares at an exchange ratio of 0.14625x. The Joint Proxy Statement/Prospectus was declared effective December 16, 2025, and both companies' special stockholder meetings are scheduled for January 29, 2026. The filing states that the supplement is being made to mitigate the risk of delay and the expense of defending several stockholder lawsuits and demand letters alleging material omissions in the proxy materials, and that Kenvue does not concede the materiality of the added disclosures.
The supplement adds background detail on the strategic review process, including the June 30, 2025 formation of a strategic review committee, an August 16, 2025 mutual non-disclosure agreement, and K-C's September 9, 2025 engagement of Gibson Dunn for product liability due diligence. It also adds fairness-opinion disclosures from Centerview Partners, Goldman Sachs and J.P. Morgan, including fee relationships, and revised valuation ranges.
Among the figures disclosed are Centerview's implied Kenvue value of $18.07 to $21.73b per share on a 2026 EBITDA multiple basis and $23.34 to $28.96 on a discounted cash flow basis, and Goldman Sachs' implied merger consideration range of $25.82 to $36.36 per Kenvue share on a pro forma basis, compared with $20.59 to $30.08 on a standalone basis. The filing also includes updated management projections for both companies and the combined business, which the filing states are not prepared under Regulation S-X.
The Kenvue board continues to unanimously recommend that Kenvue stockholders vote FOR the merger proposal, the advisory compensation proposal and the adjournment proposal. The filing contains no statement about the status of regulatory approvals or the expected closing date beyond the stockholder meeting dates.
02—Key points
Key Highlights
- Kenvue filed a voluntary supplement to its Joint Proxy Statement/Prospectus to address stockholder complaints and demand letters alleging material omissions, while stating that the disclosures are not an admission of legal necessity or materiality.
- The merger consideration includes $3.50 per Kenvue share in cash plus K-C shares at an exchange ratio of 0.14625x; both special meetings are scheduled for January 29, 2026.
- Six stockholder complaints were filed in Wisconsin, New Jersey and New York courts against Kenvue and its directors, and K-C faces a Delaware Chancery complaint filed December 29, 2025, seeking to enjoin the stockholder votes.
- Centerview's implied Kenvue value is $18.07 to $21.73 per share on a 2026 EBITDA multiple basis and $23.34 to $28.96 on a discounted cash flow basis.
- Goldman Sachs' implied merger consideration range is $25.82 to $36.36 per Kenvue share on a pro forma basis, versus $20.59 to $30.08 on a Kenvue standalone basis.
- The supplement adds updated standalone and combined management projections, including Kenvue standalone 2026E revenue of $15,448 million and Adjusted EBITDA of $3,565 million.
- The Kenvue board unanimously continues to recommend that stockholders vote FOR the merger proposal, the advisory compensation proposal and the adjournment proposal.
03—Questions
Frequently Asked Questions
What do Kenvue stockholders receive under the proposed merger?
The filing states that Kenvue stockholders (other than K-C and its affiliates) will receive $3.50 per share in cash plus K-C common stock at an exchange ratio of 0.14625x per Kenvue share under the Merger Agreement.
Why did Kenvue file this supplement?
The filing says Kenvue amended the Joint Proxy Statement/Prospectus voluntarily to avoid the risk of delaying the Mergers and to minimize the expense and distraction of defending stockholder lawsuits and demand letters alleging material omissions. It also states that the supplement is not an admission of legal necessity or materiality.
When are the stockholder votes and what is the board recommendation?
Special meetings of both Kenvue and K-C stockholders are scheduled for January 29, 2026. The Kenvue board unanimously recommends that Kenvue stockholders vote FOR the merger proposal, the advisory compensation proposal and the adjournment proposal.
What litigation is pending related to the merger?
The filing describes complaints in the U.S. District Court for the Eastern District of Wisconsin, the Superior Court of New Jersey and two complaints in the New York Supreme Court, alleging proxy disclosure omissions, plus a Delaware Chancery complaint against K-C directors filed December 29, 2025. The complaints seek, among other things, to enjoin the stockholder votes or the Mergers until corrective disclosures are made, and attorneys' fees.
How do the financial advisors value Kenvue?
Centerview's EBITDA-multiple analysis implies $18.07 to $21.73 per Kenvue share, and its discounted cash flow analysis implies $23.34 to $28.96 per share. Goldman Sachs' standalone discounted cash flow analysis implies $20.59 to $30.08 per share, and its pro forma analysis of merger consideration implies $25.82 to $36.36 per share.
04—Continue